P
Pierre Bombaron
Publications - 3
Citations - 4797
Pierre Bombaron is an academic researcher. The author has contributed to research in topics: Internal medicine & Adverse effect. The author has an hindex of 1, co-authored 1 publications receiving 4254 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer
Abdelthif Chour,Jennifer Denis,Claire Lafitte,Céline Mascaux,Michele A. Zysman,Audrey Lemaitre,Aurélie Swalduz,Valérie Gounant,Alexis B. Cortot,Marie Darrason,Jacques Cadranel,Edouard Auclin,Clémence Basse,Claire Tissot,Chantal Decroisette,Pierre Bombaron,E. Giroux-Leprieur,Lionel Falchero,Fanny Lebossé,Mickael Duruisseaux +19 more
TL;DR: Sotorasib-related adverse events (SRAE) with sequential sotorasisib following anti-PD(L)1 were described in this paper , where the adverse events were graded according to the CTCAE5 classification.
Journal ArticleDOI
Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer.
Ali Chour,Julie Denis,Céline Mascaux,Maeva Zysman,Laurence Bigay-Game,Aurélie Swalduz,Valérie Gounant,Alexis B. Cortot,Marie Darrason,Vincent Fallet,Edouard Auclin,Clémence Basse,Claire Tissot,Chantal Decroisette,Pierre Bombaron,Etienne Giroux-Leprieur,Luc Odier,Solenn Brosseau,Q. Creusot,M. Gueçamburu,Adrien Rochand,Adrien Costantini,C. Gaillard,Eric Wasielewski,Nicolas Girard,Jacques Cadranel,Claire Lafitte,Fanny Lebossé,Michael Duruisseaux +28 more
TL;DR: In this article , the authors investigated whether sequential anti-PD-(L)1 and sotorasib therapy increases the risk of hepatotoxicity and other adverse events in non-small cell lung cancer.